Picture of virus

Open Access research that helps to deliver "better medicines"...

Strathprints makes available scholarly Open Access content by the Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS), a major research centre in Scotland and amongst the UK's top schools of pharmacy.

Research at SIPBS includes the "New medicines", "Better medicines" and "Better use of medicines" research groups. Together their research explores multidisciplinary approaches to improve understanding of fundamental bioscience and identify novel therapeutic targets with the aim of developing therapeutic interventions, investigation of the development and manufacture of drug substances and products, and harnessing Scotland's rich health informatics datasets to inform stratified medicine approaches and investigate the impact of public health interventions.

Explore Open Access research by SIPBS. Or explore all of Strathclyde's Open Access research...

Cost-effectiveness analysis of introducing universal childhood rotavirus vaccination in Bangladesh

Sarker, Abdur Razzaque and Sultana, Marufa and Mahumud, Rashidul Alam and Van Der Meer, Robert and Morton, Alec (2017) Cost-effectiveness analysis of introducing universal childhood rotavirus vaccination in Bangladesh. Human Vaccines & Immunotherapeutics. ISSN 2164-554X

[img] Text (Sarker-etal-HVI-2017-Cost-effectiveness-analysis-of-introducing-universal-childhood-rotavirus-vaccination)
Accepted Author Manuscript
Restricted to Repository staff only until 3 November 2018.

Download (789kB) | Request a copy from the Strathclyde author


Diarrhoea is one of the world's leading killers of children, and globally, rotavirus is the most common cause of severe diarrhoea among under five children. In Bangladesh, rotavirus kills nearly 6,000 under five children in each year. To reduce the burden of childhood rotavirus diseases, universal rotavirus vaccination is recommended by World Health Organization. The objective of this study is to assess the cost-effectiveness of introducing universal childhood rotavirus vaccination with the newly developed ROTAVAC vaccine in national Expanded Programme of Immunization in Bangladesh. We developed a decision model to examine the potential impact of vaccination in Bangladesh and to examine the effect if the vaccination is applied in the nationwide immunization program schedule. Introduction of childhood universal rotavirus vaccination in Bangladesh scenario appears as highly cost-effective and would offer substantial future benefits for the young population if vaccinated today. The cost per DALY averted of introducing the rotavirus vaccine compared to status quo is approximately US$ 740.27 and US$ 728.67 per DALY averted from the health system and societal perspective respectively which is “very cost-effective” using GDP threshold level according to World Health Organization definition. The results of this analysis seek to contribute to an evidence-based recommendation about the introduction of universal rotavirus vaccination in national Expanded Programme of Immunization (EPI) in Bangladesh.